Memantine Reduces Premature Atrial Contractions and New-Onset Atrial Fibrillation

Premature atrial contractions are frequently encountered in clinical practice and serve as independent predictors for the development of atrial fibrillation, stroke, and heart failure [1, 2]. Despite their clinical significance, pharmacological options for suppressing these ectopies remain limited, often relying on medications with narrow therapeutic windows or significant side-effect profiles [3, 4]. Traditional antiarrhythmic strategies primarily target ion channels, yet the risk of proarrhythmia and prolongation of the corrected QT interval (the time required for the ventricles to depolarize and repolarize) remains a constant concern for clinicians managing complex patients [5, 6]. Emerging evidence suggests that the heart possesses a functional cardiac glutamatergic system (a signaling network using glutamate to modulate cellular activity), where N-methyl-D-aspartate receptors (proteins that typically act as glutamate-gated ion channels in the nervous system) play a role in regulating atrial electrophysiology [1, 7]. A new study now offers fresh insights into the efficacy and safety of targeting this pathway to manage atrial ectopy.